Melfalano Pharmexon (Melphalan)

Melphalan forms covalent cross‑links between DNA strands, preventing replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing tumor cells that have limited capacity to repair such lesions.

The dose of melphalan is individualized by the prescribing oncologist based on the specific indication, patient weight, renal function, and treatment protocol. Clinicians calculate the appropriate amount and schedule according to established clinical guidelines.

Safety data for melphalan in pregnancy and lactation are limited, and the drug is generally considered contraindicated because of potential fetal toxicity. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Melphalan is a nitrogen mustard alkylator similar to cyclophosphamide but is more lipophilic, allowing better tissue penetration. It is often preferred for high‑dose conditioning in myeloma because of its potent DNA‑cross‑linking activity, whereas cyclophosphamide has a broader safety profile and is used in a wider range of regimens.

Melfalano Pharmexon should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken. Prior to use, inspect the vial for particulate matter and ensure the solution remains clear.

The medication is supplied as a sterile solution for intra‑arterial or intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting, following aseptic technique and appropriate infusion rate guidelines.

Serious risks include secondary malignancies, severe infections due to bone‑marrow suppression, pulmonary toxicity, and renal toxicity such as hemorrhagic cystitis. Patients should be monitored closely for signs of organ dysfunction and infection throughout therapy.

Melfalano Pharmexon is contraindicated in individuals with known hypersensitivity to melphalan or its excipients, those with severe bone‑marrow failure, active uncontrolled infections, and pregnant or nursing women. Caution is also advised for patients with significant renal or hepatic impairment.